BioNTech SE is expected to report Q3 2026 consensus revenue of €1.04 billion and earnings per share of €0.70, while the stock currently trades around $88.12 against an average analyst price target of $116.72. The primary focus for investors remains the company's aggressive transition toward an oncology-first business model, specifically the anticipated €613 million milestone payment from its collaboration with Bristol Myers Squibb.
This earnings report follows a period of significant restructuring and a CEO transition designed to pivot BioNTech from its COVID-19 vaccine origins to a global multi-product immunotherapy leader. Management recently narrowed its full-year 2026 revenue guidance to a range of €1.6 billion to €1.9 billion, highlighting that growth now depends on its late-stage pipeline of over 17 clinical trials.